Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107

Che,Li-Fan; Shao,Su‑Fang; Wang,Li‑Xin

doi:10.3892/etm.2015.2911

Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107

Authors:
- Li-Fan Che
- Su‑Fang Shao
- Li‑Xin Wang
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Yi‑Du Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China
Published online on: December 4, 2015 https://doi.org/10.3892/etm.2015.2911
Pages: 503-509

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is among the most prevalent forms of cancer worldwide. C-C chemokine receptor type 5 (CCR5) is hypothesized to be a key functional protein involved in tumorigenesis. However, the role of CCR5 in cervical cancer remains unclear. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were used to evaluate the mRNA and protein expression levels of CCR5 in human cervical carcinoma tissues. Furthermore, a small interfering RNA was employed to knockdown CCR5 in HeLa and C33A cells. MTT, colony formation and Transwell assays were performed to determine the effects of this knockdown on cell viability, proliferation and invasion. In addition, micro RNA (miR)‑107 was identified as a potential candidate regulator of CCR5 using miR prediction algorithms, and the effects of miR‑107 and its antisense miR on CCR5 mRNA expression were determined. The results of the present study indicated that CCR5 is overexpressed in human cervical cancer tissues compared with adjacent normal tissues, and its downregulation inhibits cervical cancer cell growth and proliferation. Furthermore, the downregulation of CCR5 appears to suppress cervical cancer cell invasion. Finally, the tumor suppressor miR‑107 was able to directly target CCR5 and inhibit its expression. These results suggest that the upregulation of CCR5, which is inhibited by miR-107, may play a carcinogenic role in cervical cancer and could provide a novel therapeutic target in the future.

View Figures

View References

1	Bedkowska GE, Ławicki S and Szmitkowski M: Molecular markers of carcinogenesis in the diagnostics of cervical cancer. Postepy Hig Med Dosw (Online). 63:99–105. 2009.(In Polish). PubMed/NCBI
2	Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G and Selvaluxmy G: Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 11:802011. View Article : Google Scholar : PubMed/NCBI
3	Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW and Wang X: A microRNA expression signature for cervical cancer prognosis. Cancer Res. 70:1441–1448. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK and Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene. 19:2739–2744. 2000. View Article : Google Scholar : PubMed/NCBI
5	Su TH, Chang JG, Perng LI, Chang CP, Wei HJ, Wang NM and Tsai CH: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol Oncol. 76:193–199. 2000. View Article : Google Scholar : PubMed/NCBI
6	Ben-Baruch A, Michiel DF and Oppenheim JJ: Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem. 270:11703–11706. 1995. View Article : Google Scholar : PubMed/NCBI
7	Cyster JG: Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med. 189:447–450. 1999. View Article : Google Scholar : PubMed/NCBI
8	Cyster JG: Chemokines and cell migration in secondary lymphoid organs. Science. 286:2098–2102. 1999. View Article : Google Scholar : PubMed/NCBI
9	Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I and Ben-Baruch A: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59:4681–4687. 1999.PubMed/NCBI
10	Mrowietz U, Schwenk U, Maune S, Bartels J, Küpper M, Fichtner I, Schröder JM and Schadendorf D: The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer. 79:1025–1031. 1999. View Article : Google Scholar : PubMed/NCBI
11	Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE and Balkwill FR: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63:8360–8365. 2003.PubMed/NCBI
12	Ng-Cashin J, Kuhns JJ, Burkett SE, Powderly JD, Craven RR, van Deventer HW, Kirby SL and Serody JS: Host absence of CCR5 potentiates dendritic cell vaccination. J Immunol. 170:4201–4208. 2003. View Article : Google Scholar : PubMed/NCBI
13	van Deventer HW, O'Connor W Jr, Brickey WJ, Aris RM, Ting JP and Serody JS: C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res. 65:3374–3379. 2005.PubMed/NCBI
14	Son JH, Kong TW, Kim SH, Paek J, Chang SJ, Lee EJ and Ryu HS: Prediction of lymph node metastasis in patients with apparent early endometrial cancer. Obstet Gynecol Sci. 58:385–390. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wang J, He Q, Shao YG and Ji M: Chemokines fluctuate in the progression of primary breast cancer. Eur Rev Med Pharmacol Sci. 17:596–608. 2013.PubMed/NCBI
16	Lin S, Wan S, Sun L, Hu J, Fang D, Zhao R, Yuan S and Zhang L: Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 103:904–912. 2012. View Article : Google Scholar : PubMed/NCBI
17	Mango RL, Wu QP, West M, McCook EC, Serody JS and van Deventer HW: C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1. Mol Cancer Res. 12:274–282. 2014. View Article : Google Scholar : PubMed/NCBI
18	Singh H, Sachan R, Jain M and Mittal B: CCR5-Delta32 polymorphism and susceptibility to cervical cancer, Association with early stage of cervical cancer. Oncol Res. 17:87–91. 2008.PubMed/NCBI
19	Wang L, Chang L, Li Z, Gao Q, Cai D, Tian Y, Zeng L and Li M: miR-99a and −99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. Med Oncol. 31:9342014. View Article : Google Scholar : PubMed/NCBI
20	Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene. 34:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhou C, Li G, Zhou J, Han N, Liu Z and Yin J: miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. PLoS One. 9:e1118602014. View Article : Google Scholar : PubMed/NCBI
22	Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 24:4677–4684. 2006. View Article : Google Scholar : PubMed/NCBI
23	Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
24	Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, et al: A microRNA targeting dicer for metastasis control. Cell. 141:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
25	Li F, Liu B, Gao Y, Liu Y, Xu Y, Tong W and Zhang A: Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett. 588:538–544. 2014. View Article : Google Scholar : PubMed/NCBI